靶向乙肝病毒核心蛋白治疗慢性乙型肝炎的研究进展  

Research progress of targeting hepatitis B virus core protein in treatment of chronichepatitis B

作　　者：戴胜兰[1] 姚俊[1] 许亚平[1] DAI Shenglan;YAO Jun;XU Yaping(Department of Gastroenterology,People′s Hospital Affiliated to Jiangsu University,Jiangsu Province,Zhenjiang 212002,China)

机构地区：[1]江苏大学附属人民医院消化内科,江苏镇江212002

出　　处：《中国医药导报》2018年第22期35-38,共4页China Medical Herald

基　　金：江苏省镇江市科技创新(重点研发计划-社会发展)项目(SH2016040)

摘　　要：乙型肝炎病毒(HBV)核心蛋白是HBV核衣壳的组成部分,参与病毒包装、病毒成熟以及病毒向细胞外释放等过程,具有cccDNA调节功能并参与诱导机体免疫反应。本文就HBV核心蛋白的结构、功能以及在HBV治疗中的研究进展等方面,综述了近年来靶向HBV核心蛋白治疗慢性乙型肝炎的研究现状,表明核心蛋白质变构调节剂(CpAMs)可作为抗HBV药物直接靶向HBV核心蛋白而干扰其活性,利用HBV核心蛋白为靶抗原诱导HBV特异性免疫反应具有抗HBV及免疫调节作用,以期为慢性乙型肝炎的治疗发展提供参考。Hepatitis B virus(HBV)core protein is an integral part of HBV nucleocapsid,which is involved in viral packaging,viral maturation and viral releasing to the outside of cells.Core protein participates in regulation of cccDNA function and the induction of immune responses.This paper summarizes the research progress of targeting hepatitis B virus core protein in the treatment of chronic hepatitis B in recent years,starting from the structure and function of HBV core protein and the progress in the treatment of HBV.All of these indicate that core protein allosteric modulators(CpAMs)can directly interfere with the activity of HBV core protein as anti-HBV drugs,and the use of HBV core protein as a target antigen to induce HBV-specific immune responses has anti-HBV and immunomodulatory effects.These provide a theoretical reference for the development of treatment for chronic hepatitis B.

关 键 词：乙型肝炎病毒 慢性乙型肝炎 核心蛋白 共价闭合环状DNA 免疫反应 

分 类 号：R512.6[医药卫生—内科学]